^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Adenocarcinoma

    Related cancers:
    3d
    Oxidative Stress Influences Exosome Biogenesis by Inducing Cellular Senescence in Uterine Adenocarcinoma Ishikawa Cells. (PubMed, Iran J Med Sci)
    Cells were treated with 20 μM hydrogen peroxide (H2O2) for 4 days, and physicochemical properties of Exos were analyzed using dynamic light scattering (DLS), scanning electron microscope (SEM), and western blotting. The expression of genes such as ALIX, CD63, TSG101, Rab27a, and Rab27b, along with aging factor senescence-associated
    Journal
    |
    RAB27A (RAB27A, Member RAS Oncogene Family) • TSG101 (Tumor Susceptibility 101)
    9d
    Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, AstraZeneca | Trial completion date: Apr 2044 --> Nov 2043
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    16d
    PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer (clinicaltrials.gov)
    P=N/A, N=101, Active, not recruiting, M.D. Anderson Cancer Center | N=150 --> 101
    Enrollment change
    16d
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    16d
    Clinicopathologic characteristics and prognostic outcomes of surgically treated neuroendocrine cervical carcinoma: A single institution retrospective analysis. (PubMed, Int J Gynaecol Obstet)
    NECC is a highly aggressive subtype of cervical cancer, frequently associated with HPV infection-particularly HPV18-and characterized by a high risk of lymph node metastasis and poor prognosis. NECC often coexists with other malignancies. ThinPrep cytology test (TCT) combined with HPV testing may be a potential method for early detection. Surgical resection followed by adjuvant chemotherapy and/or radiotherapy may be an effective treatment strategy for early-stage NECC. FIGO stage and the extent of multiple lymph node metastases are key prognostic factors.
    Retrospective data • Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • SYP (Synaptophysin)
    18d
    Pitfalls in MLH1 promoter methylation assessment, including POLEmut/MLH1meth endometrial adenocarcinoma. (PubMed, Pathol Res Pract)
    Comprehensive genomic profiling assay was informative, allowing for correlation of MLH1 methylation and POLE genotype results with tumor mutation burden and mutational signature. Taken together, our data highlight the need for integrated approach in endometrial carcinoma biomarker testing, integrating NGS and MLH1 promoter methylation status, the latter of which benefits from assessing both regions C and D. Finding of MLH1 promoter methylation does not rule out either Lynch syndrome or ultramutated (POLE) carcinoma.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • POLE (DNA Polymerase Epsilon) • MLH1 (MutL homolog 1)
    |
    POLE mutation
    23d
    A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden. (PubMed, NPJ Precis Oncol)
    Seven tremelimumab-related serious adverse events (grade 2-3) occurred in 5 patients. While the primary PFS6 endpoint was not met, there were two durable objective responses in rare cancers and a favourable change in disease trajectory for an additional five patients based on TTP ratio 1.3.
    P2 data • Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    FoundationOne® CDx • TruSight Oncology 500 Assay • TruSight Tumor 170 Assay
    |
    Imjudo (tremelimumab-actl)
    27d
    Mesonephric-like metaplasia of the endometrium in a woman treated with letrozole: morphological, immunohistochemical and molecular analysis. (PubMed, Pathologica)
    These features appear consistent with a benign endometrial mesonephric-like metaplasia. Its relationships with hormone treatment and with MLA carcinogenesis remain to be defined.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NKX2-1 (NK2 Homeobox 1) • MME (Membrane Metalloendopeptidase) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
    |
    PIK3CA mutation • TP53 wild-type
    |
    letrozole
    1m
    Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma. (PubMed, Gynecol Oncol)
    Breast and gastric scoring criteria show high concordance in endometrial carcinoma, with discordance primarily in equivocal tumors. RNA expression may help stratify equivocal from negative cases. Further study is needed to determine whether HER2 alterations at the DNA, RNA, or protein level predict response to newer generation HER2-targeted therapies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression
    1m
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2ms
    HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology. (PubMed, Int J Mol Sci)
    Moreover, it provides a comprehension of contemporary issues in diagnostic methods and some new therapeutic approaches, suggesting the need for precision medicine in this aggressive type of cervical cancer. Further studies are necessary to enhance early detection, improve treatment results, and increase survival rates for patients with HPV-independent cervical cancer.
    Review • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • PTEN mutation • STK11 mutation
    2ms
    Case Report: A patient with lynch syndrome with vaginal endometriosis-associated malignancy and synchronous colonic tubulovillous adenoma. (PubMed, Front Med (Lausanne))
    A paclitaxel/carboplatin (TC) regimen (paclitaxel 175 mg/m2 + carboplatin AUC 5) was initiated 9 days postoperatively. This case highlights the critical importance of MMR protein testing in the screening for Lynch syndrome in patients with extra-ovarian endometriosis-associated cancer and preoperative colonoscopy. Although there are no established guidelines for the treatment of extra-ovarian endometriosis-associated cancer, its management is currently based on protocols for the treatment of primary ovarian cancer.
    Journal
    |
    MSH6 (MutS homolog 6)
    |
    carboplatin • paclitaxel